公开(公告)号：US20210403469A1

公开(公告)日：2021-12-30

申请号：US17289062

申请日：2019-11-01

Applicant: Merck Sharp & Dohme Corp.

Inventor： Yongxin Han ,  David Jonathan Bennett ,  Indu Bharathan ,  Liangqin Guo ,  Brett A. Hopkins ,  Xianhai Huang ,  Derun Li ,  Min Lu ,  Alexander Pasternak ,  David L. Sloman ,  Hongjun Zhang ,  Hua Zhou

IPC: C07D471/04 ,  C07D401/04 ,  C07D215/14 ,  C07D209/94 ,  C07D403/04

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US20200277252A1

公开(公告)日：2020-09-03

申请号：US16753035

申请日：2018-10-04

Applicant: Meredeth Ann McGowan ,  Abdelghani Achab ,  Xavier Fradera ,  Yongxin Han ,  Derun Li ,  Jongwon Lim ,  Kun Liu ,  Nunzio Sciammetta ,  Catherine M. White ,  Wensheng Yu ,  Hongjun Zhang ,  Hua Zhou ,  MERCK SHARP & DOHME CORP.

Inventor： Meredeth Ann McGowan ,  Abdelghani Achab ,  Xavier Fradera ,  Yongxin Han ,  Derun Li ,  Jongwon Lim ,  Kun Liu ,  Nunzio Sciammetta ,  Catherine M. White ,  Wensheng Yu ,  Hongjun Zhang ,  Hua Zhou

IPC: C07C237/42 ,  C07D241/24 ,  C07D213/82 ,  C07D233/90 ,  C07D263/34 ,  C07D231/14 ,  C07D277/56 ,  C07D239/28 ,  C07D213/75 ,  C07D309/14 ,  C07D237/20 ,  C07D307/14 ,  C07D205/04 ,  C07D285/06 ,  C07D487/04

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US20200095212A1

公开(公告)日：2020-03-26

申请号：US16483957

申请日：2018-02-19

Applicant: Merck Sharp & Dohme Corp.

Inventor： Kun Liu ,  Dane Clausen ,  Liangqin Guo ,  Yongxin Han ,  Shuwen He ,  Joseph Kozlowski ,  Derun Li ,  Qinglin Pu ,  Wensheng Yu ,  Hongjun Zhang

IPC: C07D271/08 ,  C07D413/12

Abstract: Compounds of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US20190276438A1

公开(公告)日：2019-09-12

申请号：US16356172

申请日：2019-03-18

Applicant: Merck Sharp & Dohme Corp.

Inventor： Blair T. Lapointe ,  Peter H. Fuller ,  Hakan Gunaydin ,  Kun Liu ,  Mark E. Scott ,  B. Wesley Trotter ,  Hongjun Zhang

IPC: C07D403/08 ,  A61P19/02 ,  C07D401/12 ,  C07D401/06 ,  C07D491/107 ,  C07D491/048 ,  C07D403/12 ,  C07D487/04 ,  C07D405/12 ,  C07D403/14 ,  C07D403/06 ,  C07D231/56 ,  C07D487/10

Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

公开(公告)号：US20180312489A1

公开(公告)日：2018-11-01

申请号：US15770256

申请日：2016-10-27

Applicant: Merck Sharp & Dohme Corp.

Inventor： Blair T. Lapointe ,  Peter H. Fuller ,  Hakan Gunaydin ,  Kun Liu ,  Mark E. Scott ,  B. Wesley Trotter ,  Hongjun Zhang

IPC: C07D403/08 ,  C07D487/10 ,  C07D403/14 ,  C07D491/107 ,  C07D487/04 ,  C07D405/12 ,  C07D401/12 ,  C07D231/56 ,  A61P19/02

CPC classification number: C07D403/08 ,  A61P19/02 ,  C07D231/56 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D487/04 ,  C07D487/10 ,  C07D491/048 ,  C07D491/107

Abstract: The present invention relates to compounds according to Formula (I) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

公开(公告)号：US09745265B2

公开(公告)日：2017-08-29

申请号：US14421048

申请日：2013-08-14

Applicant: Merck Sharp & Dohme Corp.

Inventor： Kenneth J. Barr ,  Corey E. Bienstock ,  John K. Maclean ,  Hongjun Zhang ,  Richard T. Beresis ,  Dongshan Zhang ,  Neville J. Anthony ,  Blair T. Lapointe ,  Yuan Tian

IPC: C07D209/26 ,  C07D231/56 ,  C07D471/04 ,  C07D401/04 ,  C07D403/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D413/06 ,  A61K31/404 ,  A61K31/416 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/5377 ,  C07D405/12

CPC classification number: C07D209/26 ,  A61K31/404 ,  A61K31/416 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/5377 ,  C07D231/56 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D413/04 ,  C07D413/06 ,  C07D417/04 ,  C07D471/04 ,  Y02A50/409

Abstract: The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

公开(公告)号：US09603838B2

公开(公告)日：2017-03-28

申请号：US14752195

申请日：2015-06-26

Applicant: Merck Sharp & Dohme Corp. ,  Merck Sharp & Dohme B.V.

Inventor： Willem Frederik Johan Karstens ,  Mario Van Der Stelt ,  Jos Cals ,  Rita Corte Real Goncalves Azevedo ,  Kenneth Jay Barr ,  Hongjun Zhang ,  Richard Thomas Beresis ,  Dongshan Zhang ,  Xiaobang Duan

IPC: C07D209/04 ,  C07D231/56 ,  A61K31/416 ,  C07D401/06 ,  C07D401/12 ,  C07D403/10 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  A61K31/4245 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K45/06 ,  A61K31/422

CPC classification number: A61K31/416 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K45/06 ,  C07D231/56 ,  C07D401/06 ,  C07D401/12 ,  C07D403/10 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  Y02A50/409

Abstract: The present invention relates to compounds according to Formula I or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

公开(公告)号：US20150218169A1

公开(公告)日：2015-08-06

申请号：US14421062

申请日：2013-08-14

Applicant: Merck Sharp & Dohme Corp.

Inventor： Kenneth J. Barr ,  John K. Maclean ,  Hongjun Zhang ,  Richard T. Beresis ,  Neville J. Anthony ,  Matthew Daniels ,  Blair T. Lapointe ,  Nunzio Sciammetta

IPC: C07D487/04 ,  C07D403/04 ,  A61K31/4155 ,  C07D401/04 ,  A61K31/454 ,  A61K31/46 ,  A61K31/415 ,  C07D401/14 ,  A61K31/4545 ,  A61K31/444 ,  A61K31/4439 ,  C07D451/02 ,  A61K31/437 ,  C07D231/56

CPC classification number: C07D487/04 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/46 ,  A61P5/14 ,  A61P11/06 ,  A61P17/06 ,  A61P21/00 ,  A61P25/00 ,  A61P29/00 ,  A61P33/02 ,  A61P43/00 ,  C07D213/56 ,  C07D231/56 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D451/02 ,  C07D471/04 ,  C07D519/00 ,  Y02A50/409

Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

Abstract translation: 本发明涉及式I化合物及其药学上可接受的盐或溶剂化物。 这些化合物可用于治疗RORGAMMT介导的疾病或病症。

公开(公告)号：US20150210687A1

公开(公告)日：2015-07-30

申请号：US14421052

申请日：2013-08-14

Applicant: Merck Sharp & Dohme Corp.

Inventor： Kenneth J. Barr ,  Corey E. Bienstock ,  John K. MacLean ,  Hongjun Zhang ,  Richard T. Beresis ,  Neville J. Anthony ,  Blair T. Lapointe ,  Nunzio Sciammetta

IPC: C07D471/04 ,  C07D403/06 ,  A61K31/416 ,  A61K31/437 ,  C07D231/56

CPC classification number: C07D471/04 ,  A61K31/416 ,  A61K31/437 ,  C07D231/56 ,  C07D403/06 ,  Y02A50/409

Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

Abstract translation: 本发明涉及式I化合物及其药学上可接受的盐或溶剂化物。 这些化合物可用于治疗RORGAMMT介导的疾病或病症。

公开(公告)号：US20140228348A1

公开(公告)日：2014-08-14

申请号：US14345978

申请日：2012-09-21

Applicant: MERCK SHARP& DOHME CORP.

Inventor： Jason Brubaker ,  Matthew Lloyd Childers ,  Matthew Christopher ,  Joshua T. Close ,  Jason David Katz ,  Joon Jung ,  Scott Peterson ,  Phieng Siliphaivanh ,  Tony Siu ,  Graham Frank Smith ,  Luis E. Torres ,  Hyun Chong Woo ,  Jonathan R. Young ,  Hongjun Zhang

IPC: C07D231/38 ,  C07D405/04 ,  C07D401/14 ,  C07D401/04 ,  C07D403/04

CPC classification number: C07D405/08 ,  C07D231/38 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/08 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14

Abstract: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

Abstract translation: 本发明提供了作为JAK抑制剂的式I化合物，因此可用于治疗JAK介导的疾病如类风湿性关节炎，哮喘，COPD和癌症。